In our evaluation, we excluded diagnostic biomarkers (eg, factor IX deficiency, or genetic testing for familial lipoprotein lipase deficiency) and biomarkers used to identify an established subtype of a disease (mainly ST segment elevation and non-ST segment elevation myocardial infarction). This evidence concerns the gene F9 and familial lipoprotein lipase deficiency.